ArticleCancer cell international2026
CFI-400945 enhances radiosensitivity in colorectal cancer models by promoting mitotic dysregulation and DNA damage-associated apoptosis.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRadioresistance remains a major barrier to improving radiotherapy (RT) efficacy in colorectal cancer (CRC). Since mitotic fidelity and centrosome homeostasis influence cell fate under genotoxic stress, we investigated whether CFI-400945 enhances the radiation response in CRC models and whether this effect is associated with polo-like kinase 4 (PLK4)-related mitotic dysregulation.
methodsHCT116 and HT29 CRC cells were treated with CFI-400945 and/or irradiation. Radiation response was evaluated using MTT viability and clonogenic survival assays, alongside analyses of cell-cycle distribution, centrosome-associated abnormalities, nuclear phenotypes, DNA damage-associated signaling, and apoptotic markers. PLK4 involvement was evaluated using siRNA-mediated PLK4 depletion, and Aurora kinase B (AURKB) phosphorylation was assessed to examine potential Aurora B-related effects. Combination treatment was also tested in non-malignant CCD 841 CoN colon-derived control cells and patient-derived CRC organoids.
resultsCombined CFI-400945 and RT treatment reduced short-term viability and long-term clonogenic survival in HCT116 and HT29 cells compared with either monotherapy. In CCD 841 CoN cells, CFI-400945 did not significantly enhance radiation-associated loss of clonogenic survival versus RT alone. Combination treatment increased G2/M accumulation, >4 N and sub-G1 fractions, γ-tubulin-positive foci, multinucleation, and micronucleation, consistent with centrosome-associated mitotic abnormalities and reduced survival. DNA damage-associated signaling was enhanced, with increased DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and phosphorylated histone H2AX (γH2AX) levels and increased phosphorylation of ataxia telangiectasia mutated (ATM) and CHK2. Apoptotic marker induction also increased, including robust cleavage of caspase-3 and PARP1. CFI-400945 did not markedly suppress AURKB phosphorylation under the experimental conditions. Importantly, siRNA-mediated PLK4 depletion reduced clonogenic survival after irradiation and increased cleaved PARP1 and cleaved caspase-3, supporting PLK4 involvement in the radiation response. In patient-derived CRC organoids, combination treatment reduced viability and increased DNA damage-associated and apoptotic markers compared with single treatments.
conclusionsCFI-400945 enhanced radiation response in CRC cell lines and patient-derived organoids, accompanied by centrosome-associated mitotic abnormalities, increased DNA damage-associated signaling, and apoptotic marker induction. siRNA-mediated PLK4 depletion partially recapitulated these effects, supporting a role for PLK4-associated mitotic regulation. However, because CFI-400945 may also target non-PLK4 mitotic kinases, these support an association --between radiosensitization and PLK4-related mitotic dysregulation rather than an exclusively PLK4-dependent mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.